CYNRGY Trademark

Trademark Overview


On Thursday, August 5, 2021, a trademark application was filed for CYNRGY with the United States Patent and Trademark Office. The USPTO has given the CYNRGY trademark a serial number of 90867231. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 18, 2024. This trademark is owned by EpicentRx, Inc.. The CYNRGY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products, preparations, and substances for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; immunotherapies being medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; chemical platform technology, namely, small molecule compounds ...
cynrgy

General Information


Serial Number90867231
Word MarkCYNRGY
Filing DateThursday, August 5, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 20, 2023

Trademark Statements


Goods and ServicesPharmaceutical products, preparations, and substances for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; immunotherapies being medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; chemical platform technology, namely, small molecule compounds being medical preparations for inducing the expression of antioxidant, anti-inflammatory, and cytoprotective proteins in non-malignant tissues, for activating the immune system, for modulating blood flow in ischemic tissues, for upregulating proinflammatory mediators in tumors, and for treating plant diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 30, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEpicentRx, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLa Jolla, CA 92037

Party NameEpicentRx, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLa Jolla, CA 92037

Trademark Events


Event DateEvent Description
Monday, August 9, 2021NEW APPLICATION ENTERED
Thursday, September 30, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 16, 2022ASSIGNED TO EXAMINER
Tuesday, March 22, 2022NON-FINAL ACTION WRITTEN
Tuesday, March 22, 2022NON-FINAL ACTION E-MAILED
Tuesday, March 22, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 22, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, September 22, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 23, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 1, 2022SUSPENSION LETTER WRITTEN
Tuesday, November 1, 2022LETTER OF SUSPENSION E-MAILED
Tuesday, November 1, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, May 5, 2023SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Monday, May 15, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 31, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 20, 2023PUBLISHED FOR OPPOSITION
Tuesday, June 20, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 15, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, December 22, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, December 22, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 22, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, March 18, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, March 18, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED